







**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

1. (canceled).
2. (currently amended): A compound ~~according to claim 1, depicted by one of the general formulae (III) or (VIII)~~:  
(III):





wherein

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub> and R<sub>8</sub> are independently hydrogen, hydroxy, OR<sub>9</sub>, OC(O)R<sub>9</sub>, OS(O)R<sub>9</sub>, alkyl, aryl, arylalkyl, thiol, alkylthio, bromo, chloro or fluoro,  
R<sub>9</sub> is alkyl, fluoroalkyl or arylalkyl,  
R<sub>13</sub>—R<sub>15</sub> are independently hydrogen, amino, cyano, thiol, nitro, or optionally substituted alkyl, haloalkyl, acyl, aryl, arylalkyl or alkylaryl, or the substituents R<sub>14</sub> and R<sub>15</sub> together with the nitrogen atom to which they are attached form an optionally substituted cyclic heteroalkyl or heteroaromatic structure,  
~~R<sub>16</sub>—R<sub>17</sub> are independently hydrogen, amino, cyano, thiol, nitro or optionally substituted alkyl, haloalkyl, acyl, aryl, arylalkyl or alkylaryl, or the substituents R<sub>16</sub> and R<sub>17</sub> taken together~~

~~with the carbon atom to which they are attached form an optionally substituted isoflavonoid ring system, and~~

~~the drawing "—" represents either a single bond or a double bond,  
which compounds include pharmaceutically acceptable salts thereof.~~

with the proviso that the following compounds

2,3-Dihydro-2,3-diphenyl-4H-1-benzopyran-4-one hydrazone

2'-Hydroxy-isoflavanone (2,4-dinitrophenyl)hydrazone

7-Methoxy-isoflavanone phenylhydrazone

5,7-Dimethoxy-isoflavanone (2,4-dinitrophenyl)hydrazone

Isoflavanone (2,4-dinitrophenyl)hydrazone

6-Hydroxy-isoflavanone (2,4-dinitrophenyl)hydrazone

7-Hydroxy-isoflavanone (2,4-dinitrophenyl)hydrazone

Isoflavanone semicarbazone

7-Methoxy-isoflavanone (2,4-dinitrophenyl)hydrazone

7-Hydroxy-4'-methoxy-isoflavanone (2,4-dinitrophenyl)hydrazone

5,7-Dimethoxy-isoflavanone (2,4-dinitrophenyl)hydrazone

6-Methoxy-isoflavanone (2,4-dinitrophenyl)hydrazone

4',5,7-trimethoxy-isoflavanone (2,4-dinitrophenyl)hydrazone

7-Methoxy-2-methyl-isoflavanone (2,4-dinitrophenyl)hydrazone

2-(Hydroxymethyl)-7-methoxy-isoflavanone (2,4-dinitrophenyl)hydrazone

and hydrochloride salts thereof are specifically excluded.

3. (currently amended): A compound according to claim 12, wherein R<sub>1</sub> is hydrogen,

R<sub>2</sub>, R<sub>3</sub>, R<sub>5</sub>, R<sub>6</sub> and R<sub>8</sub> are independently hydrogen, hydroxy, OR<sub>9</sub>, OC(O)R<sub>9</sub>, alkyl, aryl or arylalkyl,

R<sub>4</sub> and R<sub>7</sub> are independently hydroxy, OR<sub>9</sub> or OC(O)R<sub>9</sub>,

R<sub>9</sub> is methyl, ethyl, propyl, isopropyl or trifluoromethyl, and

~~R<sub>13</sub>~~—R<sub>14</sub> and R<sub>15</sub> are independently hydrogen, methyl, ethyl, propyl, isopropyl, trifluoromethyl or optionally substituted phenyl, naphthyl or benzyl, or the substituents R<sub>14</sub> and R<sub>15</sub> together with the nitrogen atom to which they are attached form an optionally substituted cyclic heteroalkyl or heteroaromatic structure,

which compounds include pharmaceutically acceptable salts thereof;

~~R<sub>16</sub>~~—and R<sub>17</sub> are independently hydrogen, methyl, ethyl, propyl, isopropyl, trifluoromethyl or optionally substituted phenyl, naphthyl or benzyl, or the substituents R<sub>16</sub> and R<sub>17</sub> taken together with the carbon atom to which they are attached form an optionally substituted isoflavanoid ring system, and

the drawing "—" represents either a single bond or a double bond.

4. (currently amended): A compound according to claim 23, wherein

R<sub>1</sub> is hydrogen,

R<sub>2</sub>, R<sub>3</sub>, R<sub>5</sub>, R<sub>6</sub> and R<sub>8</sub> are independently hydrogen, hydroxy, OR<sub>9</sub>, OC(O)R<sub>9</sub> or methyl,

R<sub>4</sub> and R<sub>7</sub> are independently hydroxy, OR<sub>9</sub> or OC(O)R<sub>9</sub>,

R<sub>9</sub> is methyl,

~~R<sub>13</sub>~~—is hydrogen, methyl, ethyl, trifluoromethyl, phenyl, chlorophenyl, nitrophenyl, toluyl, naphthyl, benzyl, chlorobenzyl, nitrobenzyl or methylbenzyl,

R<sub>14</sub> is hydrogen and R<sub>15</sub> is hydrogen, methyl, ethyl, trifluoromethyl, phenyl, chlorophenyl, nitrophenyl, toluyl, naphthyl, benzyl, chlorobenzyl, nitrobenzyl or methylbenzyl, or the substituents R<sub>14</sub> and R<sub>15</sub> together with the nitrogen atom to which they are attached form an optionally substituted cyclic heteroalkyl or heteroaromatic structure,

~~R<sub>16</sub>~~—and R<sub>17</sub> are independently hydrogen, methyl, ethyl, trifluoromethyl, phenyl, chlorophenyl, nitrophenyl, toluyl, naphthyl, benzyl, chlorobenzyl, nitrobenzyl or methylbenzyl, or the substituents R<sub>16</sub> and R<sub>17</sub> taken together with the carbon atom to which they are attached form an optionally substituted isoflavanoid ring system, and

the drawing "—" represents a single bond,


which compounds include pharmaceutically acceptable salts thereof.

5. (currently amended): A compound according to claim 34 selected from compounds (1) -

(10)(14):

4',7-Dihydroxyisoflavanone (phenyl)hydrazone (1)  
4',7-Dihydroxyisoflavanone (4-nitrophenyl)hydrazone (2)  
4',7-Dihydroxyisoflavanone (4-methylphenyl)hydrazone (3)  
4',7-Dihydroxyisoflavanone (benzyl)hydrazone (4)  
4',7-Dihydroxyisoflavanone (4',7-dihydroxyisoflavanone)hydrazone (5)  
4',7-Dihydroxyisoflavanone (2-chlorophenyl)hydrazone (6)  
4',7-Dihydroxyisoflavanone (3-chlorophenyl)hydrazone (7)  
4',7-Dihydroxyisoflavanone (4-chlorophenyl)hydrazone (8)  
4',7-Dihydroxyisoflavanone (2-pyridyl)hydrazone (9)  
4',7-Dihydroxyisoflavanone (4-cyanophenyl)hydrazone (10)  
~~4',7-Dihydroxy 4 methylimino isoflavan (11)~~  
~~4',7-Dihydroxyisoflavanone oxime (12)~~  
~~4-Amino 3',4' dimethoxy 7 hydroxy 8 methylisoflavan (13)~~  
~~N-[3',4' dimethoxy 7 hydroxy 8 methyl 4 chromanyl] acetamide (14)~~  
which compounds include pharmaceutically acceptable salts thereof.

6. (currently amended): A process for the preparation of a compound of formula (III) or (VIII)(I) as defined in claim 2 as claimed in claim 1 comprising the step of reacting the 4-keto group of a compound of the formula (X):



wherein

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, R<sub>8</sub> and X are as defined in claim 1, and  
the drawing "—" represents either a single bond or a double bond,

with a hydrazine an-aminating agent.

7. (currently amended): A method for the treatment, prophylaxis or amelioration of a disease or disorder which method includes the step of administering a therapeutically effective amount of one or more compounds of formula (III) or (VIII)(I) as defined in claim 2 or a pharmaceutically acceptable salt or derivative thereof to a subject;

~~with the proviso that the compounds and pharmaceutically acceptable salts of~~

~~3,4 Dihydro 3 phenyl 2H 1 benzopyran 4 amine~~

~~N(3,4 Dihydro 3 phenyl 2H 1 benzopyran 4 yl) α phenyl benzeneacetamide, and N [ 3,4 Dihydro 3 (4 hydroxyphenyl) 2H 1 benzopyran 4 yl] α phenyl benzeneacetamide are disclaimed for the treatment, prophylaxis or amelioration of atherosclerosis.~~

8. (currently amended): A method for the treatment, prevention or amelioration of diseases associated with aberrant cell survival, aberrant cell proliferation, abnormal cellular migration, abnormal angiogenesis, abnormal estrogen/androgen balance, dysfunctional or abnormal steroid genesis, degeneration including degenerative changes within blood vessel walls, inflammation, and immunological imbalance, which comprises administering to a subject one or more compounds of the formula (III) or (VIII)(I) as defined in claim 2 or a pharmaceutically acceptable salt or derivative thereof optionally in association with a carrier and/or excipient, ~~with the proviso that the compounds and pharmaceutically acceptable salts of~~

~~3,4 Dihydro 3 phenyl 2H 1 benzopyran 4 amine~~

~~N(3,4 Dihydro 3 phenyl 2H 1 benzopyran 4 yl) α phenyl benzeneacetamide, and~~

~~N [3,4 Dihydro 3 (4 hydroxyphenyl) 2H 1 benzopyran 4 yl] α phenyl benzeneacetamide are disclaimed for the treatment, prophylaxis or amelioration of atherosclerosis.~~

9. (currently amended): A method of inducing apoptosis in cells expressing abnormal prosurvival phenotype which comprises contacting said cells with one or more compounds of the formula (III) or (VIII)(I) as defined in claim 2 or a pharmaceutically acceptable salt or derivative thereof optionally in association with a carrier or excipient.

10. (currently amended): A method for inhibiting migration of cells having an abnormal cellular

migration phenotype which comprises contacting said cells with a compound of the formula (III) or (VIII)(I) as defined in claim 2 or a pharmaceutically acceptable salt or derivative thereof optionally in association with a carrier or excipient.

11. (currently amended): A method for inhibiting angiogenesis in tissue expressing aberrant angiogenic phenotype which comprises contacting said tissue with a compound of the formula (III) or (VIII)(I) as defined in claim 2 or a pharmaceutically acceptable salt or derivative thereof optionally in association with a carrier or excipient;

~~with the proviso that the compounds and pharmaceutically acceptable salts of 3,4-Dihydro 3 phenyl 2H 1 benzopyran 4 amine N(3,4 Dihydro 3 phenyl 2H 1 benzopyran 4 yl) α phenyl benzeneacetamide, and N[3,4 Dihydro 3 (4 hydroxyphenyl) 2H 1 benzopyran 4 yl] α phenyl benzeneacetamide are disclaimed for the treatment, prophylaxis or amelioration of atherosclerosis.~~

12. (currently amended): A method for the treatment, prevention or amelioration of cancer in a mammal which method comprises the step of bringing a compound of formula (III) or (VIII)(I) as defined in claim 2 or a pharmaceutically acceptable salt or derivative thereof into contact with cancerous tissue in a mammal that is suffering from a tumour, such that neoplastic development in said cancerous tissue is retarded or arrested.

13. (canceled).

14. (canceled).

15. (currently amended): An agent for the treatment, prophylaxis or amelioration of a disease or disorder, which agent comprises one or more compounds of formula (III) or (VIII)(I) as defined in claim 2 or a pharmaceutically acceptable salt or derivative thereof;  
~~with the proviso that the compounds and pharmaceutically acceptable salts of 3,4-Dihydro 3 phenyl 2H 1 benzopyran 4 amine N(3,4 Dihydro 3 phenyl 2H 1 benzopyran 4 yl) α phenyl benzeneacetamide, and N[3,4 Dihydro 3 (4 hydroxyphenyl) 2H 1 benzopyran 4 yl] α phenyl benzeneacetamide are~~

~~disclaimed for the treatment, prophylaxis or amelioration of atherosclerosis.~~

16. (currently amended): A pharmaceutical composition which comprises one or more compounds of formula (III) or (VIII)(I) as defined in claim 2 or a pharmaceutically acceptable salt or derivative thereof in association with one or more pharmaceutical carriers, excipients, auxiliaries and/or diluents, ~~with the proviso that the compounds and pharmaceutically acceptable salts of 3,4-Dihydro-3-phenyl-2H-1-benzopyran-4-amine N-(3,4-Dihydro-3-phenyl-2H-1-benzopyran-4-yl)- $\alpha$ -phenyl-benzeneacetamide, and N-[3,4-Dihydro-3-(4-hydroxyphenyl)-2H-1-benzopyran-4-yl]- $\alpha$ -phenyl-benzeneacetamide are disclaimed.~~

17. (currently amended): A drink or food-stuff, which contains one or more compounds of formula (III) or (VIII)(I) as defined in claim 2 or a pharmaceutically acceptable salt or derivative thereof.

18. (currently amended): A compound of formula (III) or (VIII)(I) as defined in claim 2 or a pharmaceutically acceptable salt thereof as herein described with reference to the Examples and/or accompanying drawings.

19. (new) A compound selected from:

4',7-Dihydroxy-4-methylimino-isoflavan (11)

4',7-Dihydroxyisoflavanone oxime (12)

4-Amino-3',4'-dimethoxy-7-hydroxy-8-methylisoflavan (13)

N-[3',4'-dimethoxy-7-hydroxy-8-methyl-4-chromanyl]-acetamide (14)

which compounds include pharmaceutically acceptable salts thereof.